<i>In vitro</i> Cytotoxicity Profiling of Croscarmellose Sodium and Selected Plasticisers on A549 and Caco-2 Cancer Cell Lines

Human exposure to pharmaceutical excipients and plasticisers is ubiquitous, comparable in vitro cytotoxicity data with human-derived cell models are rare. The cytotoxic potential of croscarmellose sodium (CCS), trioctyltrimellitate (TOTM), and bis(2-ethylhexyl) phthalate (DEHP), all routinely used to modify disintegration, flexibility and processability in pharmaceutical formulations, was evaluated using the MTT metabolic viability assay as a surrogate measure of cellular integrity and proliferative capacity. The human cell lines used were the lung adenocarcinoma (A549) and the colorectal adenocarcinoma (Caco-2) cell lines as typical pulmonary and intestinal epithelial models, respectively, and the transformed embryonic kidney line (HEK293T) as a non-epithelial comparison. Cells were treated with doses ranging from 5 to 100 µM for 24-72 h. All three compounds reduced the metabolic activity in a dose-dependent manner in A549 and Caco-2 cells, although HEK293T cells were somewhat less sensitive. CCS caused a little viability decrease, as expected from its known low toxicity. In contrast, TOTM and DEHP generated more marked cytotoxic effects and A549 cells were more susceptible than Caco-2 cells. Differential cellular susceptibility was also highlighted by divergence in calculated IC 50 values among models. These results taken together show that plasticisers are capable of producing quantifiable deleterious effects at doses typically seen. They give preliminary cytotoxicity data useful to toxicological screening and hazard identification. The results are specific to the setting of a regulatory risk assessment. Future work with mechanistic endpoints, physiologically relevant exposure doses, and in vivo validation will be important to enhance excipient safety evaluation and influence formulation design.

View article page

Download PDF